[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antipsychotic-drug\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antipsychotic-drug":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100651933","phase-1-xingqi-daozhi-decoction-for-antipsychotic-induced-constipation-100651933",false,"NCT07767526","Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation","A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial of Xingqi Daozhi Decoction for Antipsychotic-Induced Constipation With Qi Stagnation Pattern","XQD-AIC","Inclusion Criteria:\n\nMeets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia.\n\nPositive and Negative Syndrome Scale (PANSS) total score ≤95, with a PANSS negative symptom subscale score ≤28.\n\nMeets the Rome IV diagnostic criteria for functional constipation with a qi stagnation pattern.\n\nAged 18 to 65 years. Has at least a junior high school education and is able to complete self-report questionnaires.\n\nHas not used other medications known to cause constipation within the past 3 months.\n\nHas had no history of constipation within the past 2 years and no previous gastrointestinal disease.\n\nDeveloped constipation after initiation of antipsychotic medication.\n\nExclusion Criteria:\n\nMeets DSM-5 diagnostic criteria for any psychiatric disorder other than schizophrenia.\n\nIs unable to maintain a normal diet because of psychiatric symptoms, or requires a special diet such as a diabetic diet, soft diet, liquid diet, fasting, or restriction of oral intake due to individual clinical circumstances.\n\nUses other medications that may cause or aggravate constipation. Has had constipation within the past 2 years or has a history of gastrointestinal disease.\n\nHas lactose intolerance. Has clinically significant medical conditions, including diabetes mellitus, hypothyroidism, connective tissue disease, or other significant physical illnesses.\n\nIs pregnant, planning pregnancy in the near future, or breastfeeding.","ALL","18 Years","65 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Antipsychotic medications are widely used to treat schizophrenia but may cause constipation, which can lead to abdominal discomfort, reduced quality of life, and poor treatment adherence. Xingqi Daozhi Decoction is a traditional Chinese medicine formula used to relieve constipation associated with qi stagnation. This study aims to evaluate the effectiveness and safety of Xingqi Daozhi Decoction for antipsychotic-induced constipation with a qi stagnation pattern.\n\nThis is a single-center, randomized, double-blind, placebo-controlled exploratory study. A total of 46 participants with schizophrenia who developed constipation after taking antipsychotic medications will be enrolled. Participants will be randomly assigned to receive either Xingqi Daozhi Decoction granules or matching placebo granules twice daily for 8 weeks. Neither the participants nor the treating clinicians and outcome assessors will know the treatment assignment during the study.\n\nParticipants will be evaluated regularly during treatment. The study will assess changes in bowel movements, constipation symptoms, constipation-related quality of life, and treatment safety. Participants will also undergo routine clinical and laboratory safety assessments, and adverse events will be recorded throughout the study. The primary outcome focuses on the proportion of participants who achieve an improvement in complete spontaneous bowel movements during treatment.",[29,30],"Schizophrenia","Antipsychotic Drug",[29,32,33,34,35],"Xingqi Daozhi Decoction","Constipation","Antipsychotic drug","Traditional Chinese Medicine","NOT_YET_RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-17","ACTUAL",{"date":42,"type":22},"2026-10-01",{"date":44,"type":22},"2028-12-31",{"name":46,"class":47},"Shanghai Mental Health Center","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100574196","effects-of-cognitive-behavioral-therapy-through-a-mobile-app-on-patients-with-refractory-functional-dyspepsia-100574196","NCT06756139","Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia","Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia: a Multicenter, Single-blinded, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80\n2. Refractory functional dyspepsia (patients with Rome IV functional dyspepsia remained symptomatic after treatment of 8 weeks of proton pump inhibitor and 4 weeks of prokinetics)\n3. Negative or unrelated-to-FD symptom findings of gastroscopy, upper abdominal ultrasound, Hp test and routine blood tests within the past 1 year.\n\nExclusion Criteria:\n\n1. Severe mental illness (PHQ-9 ≥20 or GAD-7 ≥15) or suicidal ideation;\n2. Known hp infection, active gastrointestinal peptic ulcer, cholecystitis, gallstones, suspected or known bowel obstruction, gastroparesis, major gastrointestinal surgery etc.;\n3. Known or suspected malignant tumor, significant heart\u002Fbrain\u002Fliver\u002Fkidney diseases, obvious hematologic abnormalities or endocrine diseases etc., which may be -related to FD symptoms;\n4. Known or suspected drug-related FD (e.g.NSAIDs-related FD);\n5. Unable to access to mobile networks or unable to manage mobile APP properly.\n6. Allergy or other contradictions to flupenthixol or melitracen\n7. Taking any antipsychotics drugs or CBT interference within 12 weeks\n8. Pregnant or lactating women;\n9. Unable to provide informed consent.","80 Years",{"count":58,"type":22},88,[60],"NA","Functional dyspepsia (FD) is a common gastrointestinal disease, which is associated with decreased life quality and increased medical cost. Antipsychotic drugs were demonstrated to be effective in relieving symptoms in FD patients, especially for patients with refractory FD. However, the use of those drugs was associated with obvious adverse events. Cognitive behavioral therapy (CBT) has extensive applications and exhibited potential treatment effects in clinical practices, especially for treating anxiety, depression, pain or stress disorders. Several previous RCT studies have confirmed the effects of psychological intervention on improving dyspepsia in FD patients. Our hypothesis was that 8-week smartphone-based CBT would be non-inferior to conventional pharmacotherapy in reducing FD-related symptoms in patients with refactory FD.",[63,64,30],"Functional Dyspepsia","Self-help Mobile Cognitive Behavioral Therapy","RECRUITING","2025-06-27",{"date":68,"type":40},"2025-07-01",{"date":70,"type":40},"2024-11-01",{"date":72,"type":22},"2025-11-01",{"name":74,"class":47},"Air Force Military Medical University, China",7]